Back to Newsroom

Alder BioPharmaceuticals Appoints Elisabeth A. Sandoval as Chief Commercial Officer

Addition to Leadership Team Expands Commercialization Focus and Supports Continued Successful Advancement of ALD403 for Migraine Prevention

BOTHELL, Wash., Sept. 06, 2016 (GLOBE NEWSWIRE) — Alder BioPharmaceuticals, Inc. (NASDAQ:ALDR), a clinical-stage biopharmaceutical company developing monoclonal antibody therapeutics, today announced the appointment of Elisabeth A. Sandoval as chief commercial officer. Ms. Sandoval will be responsible for the further development and execution of the commercial strategy for ALD403, the company’s pivotal-stage product candidate for the prevention of migraine.

Click here to read the full release